Clinical Trial

A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study will measure the effects of multiple doses of AZD6234, AZD9550 and a combination of AZD9550 and AZD6234 given as injection(s) on pharmacokinetics (PK) of combined oral contraceptive (CoC) ethinyl estradiol (EE)/levonorgestrel (LEVO) in healthy female participants with obesity.
Protocol Amendment History 4 changes
minor Trial arms changed: 3 -> 4 2026-06-16
notable Primary completion pushed: 2026-12-25 -> 2027-07-09 2026-06-16
minor Completion pushed: 2026-12-25 -> 2027-07-09 2026-06-16
notable Enrollment reduced: 75 -> 50 participants 2026-04-14
Trial Details
NCT Number NCT07013643
Lead Sponsor AstraZeneca
Conditions Healthy Participants
Enrollment 50 participants
Start Date 2025-06-04
Primary Completion 2027-07-09 (estimated)
Study Completion 2027-07-09 (estimated)
Updated on ClinicalTrials.gov 2026-07-20